Valeant Pharmaceuticals Intl Inc (VRX) Shares Bought by Great West Life Assurance Co. Can

Great West Life Assurance Co. Can boosted its position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) by 3.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 248,876 shares of the specialty pharmaceutical company’s stock after buying an additional 7,511 shares during the period. Great West Life Assurance Co. Can’s holdings in Valeant Pharmaceuticals Intl were worth $2,736,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Financial Architects Inc increased its stake in shares of Valeant Pharmaceuticals Intl by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares in the last quarter. LeJeune Puetz Investment Counsel LLC purchased a new stake in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $123,000. Cambridge Advisors Inc. increased its stake in shares of Valeant Pharmaceuticals Intl by 0.6% in the first quarter. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company’s stock worth $140,000 after buying an additional 75 shares in the last quarter. Frontier Wealth Management LLC purchased a new stake in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $149,000. Finally, Private Capital Management Inc. purchased a new stake in shares of Valeant Pharmaceuticals Intl during the first quarter worth about $154,000. Institutional investors and hedge funds own 64.34% of the company’s stock.

Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) opened at 12.83 on Friday. The company has a 50-day moving average of $10.93 and a 200-day moving average of $13.52. The stock’s market capitalization is $4.46 billion. Valeant Pharmaceuticals Intl Inc has a 12 month low of $8.31 and a 12 month high of $32.74.

Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The firm had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $2.17 billion. During the same period in the prior year, the firm posted ($1.08) EPS. The firm’s revenue was down 11.1% compared to the same quarter last year. On average, equities research analysts expect that Valeant Pharmaceuticals Intl Inc will post $3.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://sleekmoney.com/valeant-pharmaceuticals-intl-inc-vrx-shares-bought-by-great-west-life-assurance-co-can/1859609.html.

A number of brokerages have recently issued reports on VRX. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price target (down previously from $21.00) on shares of Valeant Pharmaceuticals Intl in a report on Thursday, March 23rd. BTIG Research reiterated a “neutral” rating on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, May 10th. Mizuho reiterated an “underperform” rating and issued a $8.00 target price (down previously from $9.00) on shares of Valeant Pharmaceuticals Intl in a report on Monday, April 17th. BMO Capital Markets reiterated a “market perform” rating on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, May 10th. Finally, Wells Fargo & Co reiterated an “underperform” rating and issued a $8.00 target price (down previously from $11.50) on shares of Valeant Pharmaceuticals Intl in a report on Sunday, April 23rd. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $22.36.

In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De purchased 20,000 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Thursday, May 11th. The shares were bought at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the transaction, the director now owns 70,572 shares in the company, valued at approximately $980,950.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Valueact Capital Master Fund, purchased 3,000,000 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Tuesday, March 14th. The stock was acquired at an average price of $10.82 per share, for a total transaction of $32,460,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 3,054,000 shares of company stock worth $33,103,280 over the last quarter. 16.37% of the stock is currently owned by insiders.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

12 Month Chart for NYSE:VRX

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/valeant-pharmaceuticals-intl-inc-vrx-shares-bought-by-great-west-life-assurance-co-can/1859609.html

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *